| INTRODUCTION
Acute stroke including intracerebral hemorrhage (ICH) has been shown to elicit massive activation of the sympathetic nervous system responsible for complication as hypertensive derangement, cardiac changes, or immunodepression.
1,2 Thus, anti-adrenergic medication has been studied for neuroprotective properties in this setting. Previous reports indicate that prestroke beta-blocker (BB) therapy in ischemic stroke may be associated with decreased stroke severity and overall mortality. 3, 4 However, other reports contradict these findings. 5 In ICH, BB-therapy has been proposed to reduce perihematomal edema, infection rates, and mortality. [6] [7] [8] However, a huge national registry could not verify positive effects of BB on short-term mortality after ICH. 9 Given the inconclusiveness of the previous studies, we aimed to test the hypothesis that prestroke BB-therapy is associated with mortality after ICH.
| METHODS
This study was based on the Helsinki ICH Study database, a retrospective collection of all consecutive patients with ICH treated at the Helsinki University Central Hospital from January 2005 to March 2010, as published in detail previously. 10 Briefly, the database is based on retrospectively retrieved data from medical records. The Glasgow Coma Scale (GCS) was systematically registered for patients at the emergency department, and the National Institutes of Health Stroke Scale was reconstructed from chart notes. Information on comorbidities and previous medications were retrieved from the province-wide hospital notes of all specialties and general practice referral notes. All scans were evaluated by neuroradiologists at our hospital, and we included all subsequent scans after the ICH in our analysis. Lesion volumes were estimated with the ABC/2 method. 11 We recorded the modified Rankin Scale (mRS)
at discharge but did not have systematic follow-up visits, wherefore functional outcome could not be evaluated after discharge. For this reason, we used mortality as our primary outcome with date of death retrieved from Statistics Finland in October 2011 for all residents of our province. The study has been approved by institutional authorities. As a routine observational quality registry with no patient contact, consent for registration was not required by Finnish legislation. In the entire study population, in-hospital mortality was 24.1%, 3-month mortality 31.1%, and 12-month mortality 35.3%. Mortality at every time point was higher in the group of patients on pre-ICH BBtherapy as compared to BB-naïve patients. In BB-pretreated patients compared to BB-naïve patients, the in-hospital mortality, 3-months mortality, and 12-month mortality were 28.7%, 39.8%, and 46.6% as compared to 22.2%, 29.2%, and 32.3% (P = .03, P = .002, and<.001), respectively. After multivariable adjustment, no effects of prior BBtherapy on in-hospital (adjusted OR 1.1, 95% CI 0.8-1.7), 3-month mortality (adjusted OR 1.2, 95% CI 0.8-1.7), and 12-month mortality (adjusted OR 1.3, 95% CI 0.9-1.9) could be observed.
| STATISTICS

| DISCUSSION
In animal models, prestroke beta-blockade leads to decreased stroke lesion volumes, lesser infections, better functional outcome, and lower mortality. 12, 13 As increased heart rate as a surrogate for sympathetic activation has been consistently found to be associated with poor outcome and higher mortality in all stroke types, [14] [15] [16] sympatholytic therapies may appear reasonable. However, the evidence from human studies is not straight forward. Confirmatory as well as negative studies exist on the beneficial effects of the prestroke BBtherapy in acute ischemic stroke. [3] [4] [5] 9 A study by Laowattana found decreased ischemic stroke severity on admission in those taking BB-therapy. 4 On the other hand, later studies could not find any association between prestroke BB-therapy and stroke severity or outcome. 5, 17 In our previous study, we found no effects of pretreatment BB on stroke severity, mortality and functional outcome; however, patients newly started with BB within the first 3 days after onset had lower infections rates and lower mortality. 18 Interestingly, there are some positive studies of protective effects of beta-blockers in subarachnoidal hemorrhage (SAH) and traumatic brain injury (TBI), both pathologies inducing marked sympathetic hyperactivity. Study by Chalouhi suggested that pre-admission therapy with BBs may reduce the incidence of vasospasms after SAH. 19 Another study in SAH patients suggested improved discharge characteristics and lower mortality in those treated with BB. 20 For TBI, recent studies and meta-analyses consistently suggest mortality and outcome benefits with beta-blockade. [21] [22] [23] Data in patients with spontaneous ICH are scarce and include both positive and negative signals. [6] [7] [8] [9] A study by Kalita suggested reduction in mortality, SIRS, and pneumonia with the in-hospital use of atenolol in patients with ICH. 6 Other studies found no association between BB pretreatment and outcome in ICH. 7, 9 In line with the later studies, we found no effects of pre-admission BB on mortality after ICH, thus, contributing to the negative body of evidence within this topic. We hypothesize that the effects of random prestroke BB exposure and post-admission beta-blockade on stroke outcome may be different. This is also the point where most of the studies diverge. 
| CONCLUSION
In the recent large monocentric non-randomized comparison, we could not find any association of pretreatment BB with mortality after ICH.
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